Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide + G-CSF with CD34+ count-adapted plerixafor mobilization in transplant-eligible multiple myeloma after daratumumab/lenalidomide induction
KCT0009992Phase 2Withdrawn
- Sponsor
- Eunpyeong St. Mary's Hospital
- Start
- Nov 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, filgrastim and plerixafor in multiple myeloma (MM), sponsored by Eunpyeong St. Mary's Hospital. Planned start Nov 2025; status: withdrawn.
02
Drugs
etoposidefilgrastimplerixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0009992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009992.